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Background: This study aimed to estimate the age-stratified and overall morbidity and mortality 
rates of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on 
an analysis of the pervasive SARS-CoV-2 epidemic in Qatar, a country with <9% of the 
population being ≥50 years of age.  
Methods: Infection disease outcomes were investigated using a Bayesian approach applied to an 
age-structured mathematical model describing SARS-CoV-2 transmission and disease 
progression in the population. The model was fitted to infection and disease time-series and age-
stratified data. Two separate criteria for classifying morbidity were used: one based on actual 
recorded hospital admission (acute-care or intensive-care-unit hospitalization) and one based on 
clinical presentation as per World Health Organization classification of disease severity or 
criticality. 
Results: All outcomes showed very strong age dependence, with low values for those <50 years 
of age, but rapidly growing rates for those ≥50 years of age. The strong age dependence was 
particularly pronounced for infection criticality rate and infection fatality rate. Infection acute-
care and intensive-care-unit bed hospitalization rates were estimated at 13.10 (95% CI: 12.82-
13.24) and 1.60 (95% CI: 1.58-1.61) per 1,000 infections, respectively. Infection severity and 
criticality rates were estimated at 3.06 (95% CI: 3.01-3.10) and 0.68 (95% CI: 0.67-0.68) per 
1,000 infections, respectively. Infection fatality rate was estimated at 1.85 (95% CI: 1.74-1.95) 
per 10,000 infections.  
Conclusions: SARS-CoV-2 severity and fatality in Qatar was not high and demonstrated a very 
strong age dependence with <4 infections in every 1,000 being severe or critical and <2 in every 
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10,000 being fatal. Epidemic expansion in nations with young populations may lead to lower 
disease burden than previously thought. 
Keywords: Infection; SARS-CoV-2; COVID-19; severity; fatality; epidemiology; mathematical 
model; Qatar  
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The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection and associated Coronavirus Disease 2019 (COVID-19) continue to be a global health 
challenge [1]. Aside from direct implications on morbidity and mortality [1], the pandemic led to 
severe economic and societal disruptions [2], a consequence of the social and physical distancing 
restrictions imposed to slow SARS-CoV-2 transmission in view of its severity and fatality. Had 
infection severity and fatality been comparable to those of seasonal influenza or other common 
cold coronaviruses, such restrictions may not have been deemed necessary.  
One of the most affected countries by this pandemic is Qatar, a peninsula in the Arabian Gulf 
region with a population of 2.8 million [3, 4]. With its unique demographic and residential 
dwelling structure where 60% of the population are expatriate craft and manual workers 
(CMWs) living in large shared housing accommodations [3, 4], Qatar experienced a pervasive 
epidemic with >60,000 laboratory-confirmed infections per million population as of November 
23, 2020 [5, 6]. The epidemic grew rapidly starting from March 2020, peaked in late May 2020, 
then rapidly declined in subsequent weeks, and has been in a stable low-incidence phase now for 
four months (Figure S1 of Supplementary Material (SM)). A series of serological studies 
completed by November 23, 2020 suggested that about half of the population have already been 
infected [5, 7-10]. 
With a well-resourced public healthcare structure and a centralized and standardized data-capture 
system for all SARS-CoV-2 testing and COVID-19 care, Qatar has one of the most extensive 
databases to characterize this epidemic and its toll [5]. In addition to large-scale polymerase 
chain reaction (PCR) and serological testing, multiple population-based PCR and serological 
surveys have been conducted to date [5, 7-9]. As of November 23, 2020, cumulative overall 
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testing rates exceeded 638,000 per million population for PCR and 105,000 per million 
population for antibodies [11]. A comprehensive clinical characterization has also been 
completed for the hospitalized COVID-19 cases through individual chart reviews by trained 
medical personnel [11], including infection severity classification as per the World Health 
Organization (WHO) guidelines [12]. 
Given the pervasive and advanced nature of the epidemic and availability of extensive 
epidemiological data, Qatar provides a unique opportunity to assess the extent of SARS-CoV-2 
morbidity and fatality. We aimed in this study to estimate the age-stratified and overall infection 
acute-care and intensive-care-unit (ICU) hospitalization rates, infection severity and criticality 
rates, and infection fatality rate.   
Methods 
Mathematical model and parameterization 
Building on our previously developed SARS-CoV-2 models [5, 13-17], an age-structured 
deterministic mathematical model was constructed to describe SARS-CoV-2 transmission 
dynamics and disease progression in the population (Figure S2 of SM). Susceptible individuals 
in each age group were at risk of acquiring the infection based on their infectious contact rate per 
day, age-specific susceptibility to the infection, and an age-mixing matrix defining mixing 
between individuals in the different age groups. Following a latency period, infected individuals 
developed an infection that either did not require hospitalization, or that required hospitalization 
in an acute-care bed or in an ICU bed. Individuals admitted to an ICU bed had an additional risk 
for COVID-19 mortality. The model further included compartments tracking infection severity 
(asymptomatic/moderate/mild infection, severe infection, or critical infection as per WHO 
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severity classification) [12]. Population movement between model compartments was described 
using a set of coupled nonlinear differential equations (Text S1 of SM). 
The model was parameterized using best available data for SARS-CoV-2 natural history and 
epidemiology. Model parameters, definitions, and justifications can be found in Tables S1 and 
S2 of SM. The size and demographic structure of the population of Qatar were based on a 
population census conducted by Qatar’s Planning and Statistics Authority [4].  
Model fitting and analyses 
The model was fitted to extensive time-series and age-stratified data for PCR laboratory-
confirmed infections, PCR testing positivity rate, antibody testing positivity rate, PCR and 
serological surveys, daily hospital admissions in acute-care and ICU beds, hospital occupancy in 
acute-care and ICU beds, incidence of severe and critical infections as per WHO classification 
[12], and COVID-19 deaths (further details in Text S2 of SM). A Bayesian method, based on the 
incremental mixture importance sampling with shot-gun optimization [18, 19], was used to fit 
the model to the different data sources and to estimate the mean and 95% credible interval (CI) 
for each estimated parameter (Text S2 of SM). The model was coded, fitted, and analyzed using 
MATLAB R2019a [20]. 
Outcome measures 
Table 1 provides a listing of each outcome measure estimated in this study, its definition, and its 
interpretation. Two sets of outcome measures were generated. The first set includes crude case 
rates, such as the crude case fatality rate, calculated as the cumulative number of a disease 
outcome (say COVID-19 death) over the cumulative number of documented (that is PCR 
laboratory-confirmed) infections.  
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The second set includes infection rates, such as the infection fatality rate, calculated as the 
cumulative number of a disease outcome (say COVID-19 death) over the model-estimated 
cumulative number of infections, documented and undocumented.  
Two separate criteria for classifying morbidity were used: one based on actual recorded hospital 
admission (acute-care or ICU) and one based on clinical presentation as per WHO classification 
of disease severity [12]. While the two are overlapping with severe cases typically admitted to 
acute-care beds, and critically ill cases admitted to ICU beds, a significant fraction of mild or 
moderately ill cases were hospitalized out of caution. Moreover, hospitalization was used as a 
form of case isolation earlier in the epidemic. Of note that the health system in Qatar remained 
well within its threshold even at the epidemic peak towards end of May 2020.    
Results 
Figure 1A shows the crude case acute-care and ICU bed hospitalization rate versus time. The 
rate was rather stable, but with a slightly declining trend, and was assessed at 113.9 acute-care 
and/or ICU hospital admissions per 1,000 laboratory-confirmed infections on November 22, 
2020. As of this date, a total of 18,509 acute-care and 1,759 ICU hospital admissions had been 
registered.  
Figure 1B shows the crude case severity and criticality rate versus time. The rate was rather 
stable, but with a slightly declining trend, and was assessed at 28.0 severe and/or critical cases 
per 1,000 laboratory-confirmed infections on November 22, 2020. As of this date, a total of 
4,127 severe and 863 critical infections had been registered. 
Figure 1C shows the crude case fatality rate versus time. The rate increased over time, as 
expected with the weeks-long delay between infection and eventual COVID-19 death, but then 
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stabilized as the epidemic entered its low but stable infection incidence phase (Figure S1 of SM). 
The rate was assessed at 13.2 deaths per 10,000 laboratory-confirmed infections on November 
22, 2020. As of this date, a total of 235 COVID-19 deaths had been registered. 
The model produced robust fits to each dataset. Table S3 of SM summarizes the goodness-of-fit. 
Figures S3-S7 of SM show the age-specific posterior distributions of the infection acute-care bed 
hospitalization rate (Figure S3), infection ICU bed hospitalization rate (Figure S4), infection 
severity rate (Figure S5), infection criticality rate (Figure S6), and infection fatality rate (Figure 
S7). Meanwhile, Figures S8-S9 of SM show the overall (total population of all age groups) 
infection acute-care bed hospitalization rate (Figure S8A), infection ICU bed hospitalization rate 
(Figure S8B), infection severity rate (Figure S8C), infection criticality rate (Figure S8D), and 
infection fatality rate (Figure S9). 
Table 2, Figure 2, and Figure 3A show the estimated mean and 95% CI of all age-specific 
infection rate measures. All rates showed very strong age dependence. Measures increased 
steadily with age, with low values for those <50 years of age, but very rapidly growing rates for 
those ≥50 years of age. The strong age dependence was even more pronounced for infection ICU 
bed hospitalization rate (Figure 2B), infection criticality rate (Figure 2D), and infection fatality 
rate (Figure 3A). 
The overall (total population of all age groups) infection acute-care bed hospitalization rate was 
estimated at 13.10 (95% CI: 12.82-13.24) per 1,000 infections, infection ICU bed hospitalization 
rate at 1.60 (95% CI: 1.58-1.61) per 1,000 infections, infection severity rate at 3.06 (95% CI: 
3.01-3.10) per 1,000 infections, infection criticality rate at 0.68 (95% CI: 0.67-0.68) per 1,000 
infections, and infection fatality rate at 1.85 (95% CI: 1.74-1.95) per 10,000 infections.  
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Figure 1D shows the infection acute-care and ICU bed hospitalization rate versus time. The rate 
increased over time, as expected with the delay between infection and hospital admission, but 
then stabilized (Figure 1D) as the epidemic peaked and started to decline (Figure S1 of SM). The 
rate was assessed at 13.8 hospital admissions per 1,000 infections on November 22, 2020. A 
similar pattern was found for the infection severity and criticality rate (Figure 1E) and infection 
fatality rate (Figure 1F), which were assessed at 3.4 cases per 1,000 infections and 1.6 deaths per 
10,000 infections, respectively, on November 22, 2020. 
The study generated other relevant estimates. The diagnosis (detection) rate as of November 22, 
2020, that is the proportion of infections that were documented (with PCR laboratory-confirmed 
diagnosis) out of all infections that were estimated to have occurred, was assessed at 12.1% 
(95% CI: 12.0-12.1%). The mean duration of acute-care hospitalization was estimated at 8.73 
(95% CI: 8.62-8.83) days and the mean duration of ICU hospitalization was estimated at 12.30 
(95% CI: 12.18-12.41) days. 
Discussion 
The striking finding of this study is that SARS-CoV-2 morbidity and mortality demonstrated a 
very strong age dependence. Infection severity, criticality, and fatality increased very rapidly 
with age. This was particularly the case for infection criticality and fatality which were limited 
for those <50 years of age but increased very rapidly for those ≥50 years of age (Figures 2-3). 
This strong age dependence combined with the lower infection exposure in those ≥60 years of 
age (Figure S10 of SM) and the small proportion of the population ≥50 years of age (9%) and 
≥60 years of age (2%), all contributed together to a low morbidity and mortality in Qatar. Out of 
every 1,000 infections, only 3.7 infections were destined to be severe or critical, and out of every 
10,000 infections, only 1.9 infections were destined to end in COVID-19 death (Table 2).  
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Notably, both SARS-CoV-2 morbidity and mortality in Qatar were not much higher than those 
typically seen in a seasonal influenza epidemic in the United States [21, 22]. This fact, however, 
needs to be interpreted in context. With the young age structure of the population in Qatar, a 
seasonal influenza epidemic in this country has a much lower severity than that in the United 
States. Typically, only a handful of influenza-related deaths are reported every year in Qatar 
[23]. 
Other lines of evidence support these findings. In a survey of ten CMW communities in Qatar, 
only five severe infections and one critical infection ever occurred in 3,233 persons with 
confirmed infection (antibody and/or PCR positive result), that is an infection severity and 
criticality rate of 2.5 (95% CI: 1.1-4.9) per 1,000 infections [7]. In another nationwide survey of 
the CMW population, only seven severe infections and one critical infection ever occurred in 
1,590 persons with antibody and/or PCR positive result, an infection severity and criticality rate 
of 5.0 (95% CI: 2.2-9.9) per 1,000 infections [8]. Both of these estimates are in agreement with 
the present study estimate of 3.7 (95% CI: 3.7-3.8) per 1,000 infections.  
These figures, however, are substantially lower than those estimated elsewhere, often using early 
epidemic data [24-29]. The fact that the early phases of the epidemic in Europe and the United 
States heavily affected nursing facilities and care homes of the elderly may have biased the 
estimates to higher values. It is also possible that our estimates are lower because of the robust 
accounting of the large pool of undocumented infections in the present study, thanks to the series 
of serological surveys conducted in Qatar [5, 7-10]. These surveys provided some of the key 
input data for this modeling study. For instance, the nationwide survey of the CMW population 
found that only 9.3% (95% CI: 7.9-11.0%) of those antibody positive had a prior documented 
PCR laboratory-confirmed infection [8]. This is in agreement with the diagnosis (detection) rate 
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estimated here at 12.1% (95% CI: 12.0-12.1%), as well as growing evidence from other countries 
indicating that only one in every 10 infections was ever diagnosed [24, 30-33]. The totality of 
evidence on the Qatar epidemic also indicates that most infections were asymptomatic or 
minimally mild to be diagnosed [5-9, 34-36]. For instance, a national SARS-CoV-2 PCR survey 
found that 58.5% of those testing PCR positive reported no symptoms within the preceding two 
weeks of the survey [5]. 
In light of these findings, it is evident that the strong age dependence of SARS-CoV-2 morbidity 
and mortality is a principal contributor to the low morbidity and mortality seen in Qatar 
compared to elsewhere. The impact of this strong age dependence is illustrated in Figure 3B 
where the age-specific infection fatality rate of Table 2 has been applied to the age structure of 
other national populations. The infection fatality rate in Italy was found to be 10-fold higher than 
that in Qatar, only because of the population’s different age structure. These findings indicate 
that the infection morbidity and mortality may vary immensely across countries, and will be 
substantially lower in countries with younger demographic structures, as suggested earlier [13].   
While age appears to be the principal factor, other factors could have also contributed to 
explaining the low morbidity and mortality in Qatar. Growing evidence indicates T cell and 
antibody reactivity against SARS-CoV-2 in unexposed individuals [37-40], that probably reflects 
development of T cell and antibody immune memory to circulating ‘common cold’ 
coronaviruses, which may have in turn led to lower morbidity and mortality [37-40]. The shared-
housing dwelling structure in Qatar that contributed to the large SARS-CoV-2 epidemic [5] may 
have, along with the frequent international travel of Qatar’s expatriate population, also 
contributed to higher levels of exposure to other common cold coronaviruses [41, 42], thereby 
inducing high levels of broadly cross-reactive T cell and antibody responses. Such pre-existing 
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immune reactivity [37-40] may have thus resulted in lower levels of SARS-CoV-2 morbidity and 
mortality in the population of Qatar.    
The resourced healthcare system, which was well below its threshold even at the epidemic peak, 
may have also contributed to the low observed morbidity and mortality. Emphasis on proactive 
early treatment, in addition to a cautious approach for SARS-CoV-2 case management, may have 
limited the number of people who went on to require hospitalization, or to develop severe or 
critical disease.  
Limitations may have affected this study. We estimated rates of infection morbidity and 
mortality, not accounting for potential differences by sex, comorbidities, or other factors. Model 
estimations are contingent on the validity and generalizability of input data. Available input data 
were most complete at the national level, and although there could be subpopulation differences 
in the highly diverse population of Qatar, these could not be factored in the model given 
insufficient data at the subpopulation level. Despite these limitations, our model, tailored to the 
complexity of the epidemic in Qatar, was able to reproduce the observed epidemic trends, and 
provided profound insights about healthcare needs and infection morbidity and mortality.   
In conclusion, SARS-CoV-2 morbidity and mortality demonstrate a strikingly strong age 
dependence. With its young population structure, both morbidity and mortality were low in 
Qatar, and not much higher than those typically seen in a seasonal influenza epidemic in the 
United States [21, 22]. Out of every 1,000 infections, only 3.7 infections were severe or critical, 
and out of every 10,000 infections, only 1.9 infections were fatal. However, these rates would 
have been much higher if the population of Qatar had a similar demographic structure to that 
found in Europe or the United States. These findings suggest that SARS-CoV-2 morbidity and 
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mortality may vary immensely by country or region, and that the pandemic expansion in nations 
with young populations may lead to much milder disease burden than currently believed.  
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Table 1. Crude case rates and infection rates estimated in this study.  
Outcome measure Definition Interpretation 
Crude case rates-data estimation 
1. Crude acute-care and ICU bed 
hospitalization rate 
Cumulative number of hospital admissions into 
acute-care or ICU beds over the cumulative number 
of documented PCR laboratory-confirmed infections 
Proportion of PCR laboratory-confirmed 
infections that progressed to hospital 
admission into acute-care or ICU beds 
2. Crude case severity and criticality rate Cumulative number of COVID-19 severe or critical 
infections* over the cumulative number of 
documented PCR laboratory-confirmed infections 
Proportion of PCR laboratory-confirmed 
infections that progressed to become 
severe or critical 
3. Crude case fatality rate Cumulative number of COVID-19 deaths over the 
cumulative number of documented PCR laboratory-
confirmed infections 
Proportion of PCR laboratory-confirmed 
infections that ended in COVID-19 death  
Infection rates-model estimation 
1. Infection acute-care bed hospitalization 
rate 
Cumulative number of hospital admissions into 
acute-care beds over the cumulative number of 
infections, documented and undocumented 
Proportion of infections that progressed 
to acute-care bed hospital admission  
2. Infection ICU bed hospitalization rate Cumulative number of hospital admissions into ICU 
beds over the cumulative number of infections, 
documented and undocumented 
Proportion of infections that progressed 
to ICU bed hospital admission 
3. Infection severity rate Cumulative number of COVID-19 severe infections* 
over the cumulative number of infections, 
documented and undocumented 
Proportion of infections that progressed 
to become severe infections 
4. Infection criticality rate Cumulative number of COVID-19 critical infections* 
over the cumulative number of infections, 
documented and undocumented 
Proportion of infections that progressed 
to become critical infections 
5. Infection fatality rate Cumulative number of COVID-19 deaths over the 
cumulative number of infections, documented and 
undocumented 
Proportion of infections that ended in 
COVID-19 death 
Combined infection rates-model estimation 
1. Infection acute-care and ICU bed 
hospitalization rate 
Cumulative number of admissions into acute-care or 
ICU beds over the cumulative number of infections, 
documented and undocumented 
Proportion of infections that progressed 
to acute-care or ICU bed hospital 
admission 
2. Infection severity and criticality rates Cumulative number of COVID-19 severe or critical 
infections* over the cumulative number of infections, 
documented and undocumented 
Proportion of infections that progressed 
to become severe or critical infections 
*Per World Health Organization (WHO) infection severity classification [12].  
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Figure 1. Temporal trend in A) crude case acute-care and ICU bed hospitalization rate, B) crude 
case severity and criticality rate, C) crude case fatality rate, D) infection acute-care and ICU bed 
hospitalization rate, E) infection severity and criticality rate, and F) infection fatality rate. 
Classification of infection severity and criticality was per WHO infection severity classification 
[12]. 
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Table 2. Estimated mean and 95% credible interval (CI) of the age-specific infection acute-care and ICU bed hospitalization rates, 
infection severity and criticality rates, and infection fatality rate. Classification of infection severity and criticality was per WHO 
infection severity classification [12]. 
Age group 
(years) 
Infection acute-care bed 
hospitalization rate 
(per 1,000 infections) 
Infection ICU bed 
hospitalization rate 
(per 1,000 infections) 
Infection severity rate 
(per 1,000 infections) 
Infection criticality rate 
(per 1,000 infections) 
Infection fatality rate 
(per 10,000 infections) 
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
0-9 8.06 (7.85-8.20) 0.44 (0.43-0.46) 0.07 (0.07-0.08) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 
10-19 7.15 (6.96-7.27) 0.39 (0.38-0.41) 0.13 (0.13-0.13) 0.04 (0.04-0.04) 0.00 (0.00-0.00) 
20-29 7.19 (7.02-7.28) 0.40 (0.39-0.41) 0.47 (0.46-0.48) 0.08 (0.08-0.08) 0.12 (0.11-0.13) 
30-39 10.07 (9.88-10.18) 0.71 (0.69-0.72) 1.86 (1.83-1.89) 0.21 (0.21-0.21) 0.09 (0.09-0.10) 
40-49 16.00 (15.65-16.17) 1.92 (1.90-1.94) 4.05 (3.99-4.11) 0.73 (0.72-0.73)  0.75 (0.70-0.80) 
50-59 26.35 (25.69-26.68) 4.67 (4.63-4.70) 8.35 (8.22-8.48) 2.10 (2.08-2.12) 5.31 (4.99-5.65) 
60-69 60.46 (58.82-61.53) 12.65 (12.54-12.75) 25.08 (24.70-25.48) 7.43 (7.37-7.49) 27.68 (26.15-29.26) 
70-79 99.84 (97.23-101.65) 38.03 (37.72-38.32) 50.16 (49.39-50.95) 22.45 (22.25-22.62) 116.44 (110.43-122.83) 
80+ 36.73 (35.76-37.37) 32.94 (32.60-33.26) 31.26 (30.78-31.76) 23.02 (22.82-23.19) 175.76 (168.92-183.17) 
Overall 
population 
13.10 (12.82-13.24) 1.60 (1.58-1.61) 3.06 (3.01-3.10) 0.68 (0.67-0.68) 1.85 (1.74-1.95) 
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Figure 2. The age-specific A) infection acute-care bed hospitalization rate, B) infection ICU bed 
hospitalization rate, C) infection severity rate, and D) infection criticality rate. Classification of 
infection severity and criticality was per WHO severity classification [12]. 
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Figure 3. A) The age-specific infection fatality rate in Qatar. B) Estimated overall (total 
population of all age groups) infection fatality rate for several select countries that are 
characterized by diverse demographic structures. The estimates were generated by applying the 
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Figure S1. Time course of the SARS-CoV-2 epidemic in Qatar. Daily incidence of (A) 
documented laboratory-confirmed infections and (B) documented and undocumented infections 
estimated by the model.  
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Text S1. Mathematical model structure and description 
We constructed an age-structured deterministic mathematical model to describe the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission dynamics and disease 
progression in the population of Qatar (Figure S1). The model stratified the population into 
compartments according to age group (0-9, 10-19, 20-29,…, ≥80 years), infection stage (does not 
require hospitalization, requires acute-care hospitalization, requires intensive care unit (ICU) 
hospitalization), and hospitalization stage (acute-care hospitalization, ICU hospitalization). The 
model also includes five tracking compartments to track infection severity 
(asymptomatic/moderate/mild infection, severe infection, severe disease, critical infection, 
critical disease per World Health Organization (WHO) severity classification [1]). The model 
extends our earlier mathematical models developed to characterize SARS-CoV-2 epidemics [2-
5].  
Epidemic dynamics were described using age-specific sets of coupled nonlinear differential 
equations. Each age group, a , denoted a ten-year age band apart from the last category which 
grouped together all individuals ≥80 years of age. Qatar’s population size and demographic 
structure were based on findings of “The Simplified Census of Population, Housing, and 
Establishments” conducted by Qatar’s Planning and Statistics Authority [6]. Life expectancy was 
obtained from the United Nations World Population Prospects database [7].   
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Figure S2. Schematic diagram describing the basic structure of the SARS-CoV-2 mathematical model and its associated tracking 
compartments. 
 
*Per World Health Organization (WHO) infection severity classification [1] 
**ICU: intensive care unit
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The following equations were used to describe the transmission dynamics in the total population: 
( ) ( ) ( )( )
( )
1 ( 1) ( )
dS a
a S a a a S a
dt
   = − − − + +  
( ) ( ) ( ) ( )( )
( )
1 ( 1) ( )
dE a
a E a a S a a E a
dt
    = − − + − + +   
( ) ( ) ( ) ( )( )
( )
1 ( 1) ( )NoH NoH NoH NoH NoH
dI a
a I a f a E a a I a
dt
    = − − + − + +  
( ) ( ) ( )( )
( )
1 ( 1) ( ) ( )Acute Care Acute Care Acute Care A Acute Care
dI a
a I a f a E a a I a
dt
    − − − −= − − + − + +  
( ) ( ) ( )( )
( )
1 ( 1) ( ) ( )ICU ICU ICU I ICU
dI a
a I a f a E a a I a
dt
    = − − + − + +  
( ) ( ) ( )( )
( )
1 ( 1) ( )Acute Care Acute Care A Acute Care AH AI Acute Care
dH a
a H a I a a H a
dt
     − − − −= − − + − + + +  
( ) ( ) ( ) ( ) ( )( )
( )
1 ( 1) ( )ICU ICU I ICU AI Acute Care IH ICU
dH a
a H a I a H a a a H a
dt
      −= − − + + − + + +  
( ) ( )( )
( )
1 ( 1) ( ) ( ) ( ) ( )NoH NoH AH Acute Care IH ICU
dR a
a R a I a H a H a a R a
dt
     −= − − + + + − +   
The following equations were used to track the individuals who have 
asymptomatic/moderate/mild infection, severe infection, severe disease, critical infection, and 
critical disease per WHO infection severity classification [1]: 
( ) ( ) ( )( )
( )
1 ( 1) ( ) ( )M M M M
dI a
a I a f a E a a I a
dt
   = − − + − +
( ) ( ) ( )( )
( )
1 ( 1) ( ) ( )S S S S S
dI a
a I a f a E a a I a
dt
    = − − + − + +  
( ) ( ) ( )( )
( )
1 ( 1) ( ) ( )C C C C C
dI a
a I a f a E a a I a
dt
    = − − + − + +  
( ) ( ) ( )( )
( )
1 ( 1) ( )S S S S S
dD a
a D a I a a D a
dt
   = − − + − +  
( ) ( ) ( )( )
( )
1 ( 1) ( )C C C C C
dD a
a D a I a a D a
dt
   = − − + − +  
The definitions of population variables and symbols used in the equations are listed in Table S1. 
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Table S1. Definitions of population variables and symbols used in the model. 
Symbol Definition 
( )S a   Susceptible population  
( )E a   Latently infected population  
( )NoHI a   Population that is infectious but with an infection that will not require hospitalization 
( )Acute CareI a−   Population that is infectious and that will progress to acute-care hospitalization 
( )ICUI a   Population that is infectious and that will progress to ICU hospitalization  
( )Acute CareH a−   Population with hospitalization in acute-care beds 
( )ICUH a   Population with hospitalization in ICU beds 
( )R a   Recovered population 
( )MI a   Population with an asymptomatic/moderate/mild infection per WHO infection 
severity classification [1] 
( )SI a    
Population with an infection that will progress to severe disease per WHO infection 
severity classification [1] 
( )CI a   Population with an infection that will progress to critical disease per WHO infection 
severity classification [1] 
( )SD a   Population with severe disease per WHO infection severity classification [1] 
( )CD a   Population with critical disease per WHO infection severity classification [1] 
agen   Number of age groups 
( )a   Transition rate from one age group to the next age group. Here (0) ( ) 0agen = =  
( )a   Susceptibility profile to the infection in each age group  
1/  Duration of latent infection before onset of infectiousness 
   Average rate of infectious contacts  
1/ 1/ 1/NoH A I  = =  Duration of infectiousness 
1/ AH  Duration of acute-care hospitalization following hospital admission and prior to 
recovery  
1/ IH  Duration of ICU hospitalization following hospital admission and prior to recovery 
1/ AI   Duration of acute-care hospitalization prior to admission to ICU for those infected 
individuals that are transferred from acute-care to ICU 
1/ S  Duration of severe infection prior to onset of severe disease 
1/ C   Duration of critical infection prior to onset of critical disease  
  Natural death rate 
( )a   Disease mortality rate in each age group  
( )NoHf a   Proportion of infections that will progress to be infections that will not require 
hospitalization 
( )Acute Caref a−   Proportion of infections that will progress to be infections that require hospitalization 
in acute-care beds 
( )ICUf a   Proportion of infections that will progress to be infections that require hospitalization 
in ICU beds 
( )Mf a   
 
Proportion of infections that are asymptomatic/moderate/mild per WHO infection 
severity classification [1] 
( )Sf a   Proportion of infections that will progress to be severe infections per WHO infection 
severity classification [1] 
( )Cf a   Proportion of infections that will progress to be critical infections per WHO infection 
severity classification [1] 
All rights reserved. No reuse allowed without permission. 
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 




The force of infection (hazard rate of infection) experienced by each susceptible population, 
( )S a , is given by 
( ) ( ) ( )
,
1
( ) ( ) ( )




NoH Acute Care ICU
a NoH Acute Care ICU Acute Care ICU
I a I a I a
a t a





  + +
=
        + + + + + + + 
H  
Here, ( )t  is the time-dependent average rate of infectious contacts and ( )a  is the 
susceptibility profile to the infection in each age group a . To account for temporal variation in 
the basic reproduction number, we incorporated a temporal variation in    that was 





Woods-Saxon               Logistic
          
1 1
       











This function was mathematically designed to describe and characterize the time evolution of the 
level of risk of exposure before and after easing of restrictions. It was informed by our 
knowledge of SARS-CoV-2 epidemiology in Qatar [3], and it provided a robust fit to the data. 
Here 
1a , 2a , 1b , 2b , 1c , and 2c  are fitting parameters. 
The probability that an individual in the a  age group will mix with an individual in the a  age 
group is determined by an age-mixing matrix, 
,a a
H , given by 
, ,
1
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
(1 )
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
a a age
NoH Acute Care ICU Acute Care ICU
Age a a Age n
NoH Acute Care ICU Acute Care ICU
a
S a E a I a I a I a H a H a R a
e e







       + + + + + + +
= + −
        + + + + + + + 
H  
Here, ,a a   is the identity matrix and  0,1Agee   measures the degree of assortativeness in the 
age mixing. At the extreme 0Agee = , the mixing is fully proportional, while at the other extreme, 
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1Agee = , the mixing is fully assortative, that is individuals mix only with members in their own 
age group. 
Text S2. Parameter values, data input, and model fitting 
Model input parameters were based on best available empirical data for SARS-CoV-2 natural 
history and epidemiology. Model input parameter values and supporting evidence are listed in 
Table S2.  
Table S2. Model input parameters. 
Parameter Symbol Value Justification 
Duration of latent infection 
 
1/  3.69 days Based on existing estimate [8] and based on a 
median incubation period of 5.1 days [9] 
adjusted by observed viral load among infected 
persons [10] and reported transmission before 
onset of symptoms [11] 
Duration of infectiousness 
 
1/ NoH ;
1/ A ; 
1/ I  
3.48 days Based on existing estimate [8] and based on 
observed time to recovery among persons with 
mild infection [8, 12] and observed viral load 
in infected persons [10, 11, 13]
 
Life expectancy in Qatar 1/   80.7 years United Nations World Population Prospects 
database [7] 
 
The model was fitted to extensive sources of data thanks to the centralized and standardized 
databases of SARS-CoV-2 testing, infection, COVID-19 disease, hospitalization, and severity as 
well as to findings of ongoing epidemiologic studies in Qatar. Data included: 1) time-series of 
number of PCR laboratory-confirmed SARS-CoV-2 infections, 2) distribution of PCR 
laboratory-confirmed infections by age group, 3) time-series of SARS-CoV-2 PCR testing 
positivity rate, 4) fraction of PCR laboratory-confirmed SARS-CoV-2 infected persons aged >60 
years old, 5) a series of PCR and serological surveys, 6) age-distribution of SARS-CoV-2 
antibody positivity, 7) time-series of new/daily hospital admissions in acute-care beds and in 
ICU beds, 8) age distribution of hospital admissions in acute-care beds and in ICU beds, 9) 
fraction of individuals admitted to ICU beds from acute-care beds, 10) time-series of current 
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hospital occupancy in acute-care beds and in ICU beds, 11) time-series of new/daily severe 
infections and critical infections per WHO infection severity classification [1], 12) age 
distribution of severe and critical infections per WHO infection severity classification [1], 13) 
time series of COVID-19 deaths, and 14) age distribution of COVID-19 deaths. 
A Bayesian method, based on incremental mixture importance sampling with shotgun 
optimization [14, 15], was used to conduct the model fitting and generate posteriors and credible 
sets. In the first stage (initialization), the importance sampling distribution was initialized by 
drawing a large number of points from the prior distribution and weights were attached to each 
point using their respective log-likelihood.  
In the second stage (shot-gun optimization), multiple sequential optimizations were carried out. 
In each of these, the point of the importance sampling distribution with the maximum weight was 
computed, and a new sample set was drawn from a Gaussian distribution centered at this point. 
The local maximum of this sample set (point with largest log-likelihood) was then identified. 
The importance sampling distribution was then updated to exclude the points that are farthest 
from this local maximum in terms of Mahalanobis distance. A new sample set was then drawn 
from a Gaussian distribution centered at the current local maximum and was added to the 
importance sampling distribution. At the end of the shot-gun optimization stage, a candidate 
importance sampling distribution was obtained.  
In the third stage (importance sampling), weights were attached to each point in the importance 
sampling distribution and sampling was iterated until convergence in the distribution of the 
importance sampling distribution. In the fourth stage (resampling), points were resampled from 
the importance sampling distribution to construct the posterior distribution of each estimated 
parameter. 
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Table S3. Goodness-of-fit in terms of likelihood of the model fitting each dataset. 
Empirical dataset Model fitting likelihood 
Time-series of number of PCR laboratory-confirmed SARS-CoV-2 infections 80.52% 
Distribution of PCR laboratory-confirmed infections by age group 82.34% 
Time-series of SARS-CoV-2 PCR testing positivity rate 81.81% 
Fraction of PCR laboratory-confirmed SARS-CoV-2 infections aged >60 years 98.10% 
Series of PCR surveys 89.31% 
Age-distribution of SARS-CoV-2 antibody positivity 99.17% 
Time-series of new/daily hospital admissions in acute-care and in ICU beds 98.87% 
Age distribution of hospital admissions in acute-care and in ICU beds 99.95% 
Fraction of ICU admissions that are being transferred from acute-care beds  99.99% 
Time-series of current hospital occupancy in acute-care and in ICU beds 93.53% 
Time-series of new/daily severe infections and critical infections* 99.43% 
Age distribution of severe and critical infections* 99.96% 
Age distribution of COVID-19 deaths 99.98% 
*Per World Health Organization (WHO) infection severity classification [1] 
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Figure S3. Posterior distribution of the age-specific infection acute-care bed hospitalization rate. 
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Figure S5. Posterior distribution of the age-specific infection severity rate. Classification of 
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Figure S6. Posterior distribution of the age-specific infection criticality rate. Classification of 
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Figure S7. Posterior distribution of the age-specific infection fatality rate.  
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Figure S8. Posterior distribution of the overall (total population of all age groups) A) infection 
acute-care bed hospitalization rate, B) infection ICU bed hospitalization rate, C) infection 
severity rate, and D) infection criticality rate. 
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Figure S10. The SARS-CoV-2 age-specific antibody prevalence (seroprevalence) in the total 
population of Qatar based on compilation and analysis of seroprevalence data from a series of 
serological studies [3, 16-19].  
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